Delivery Order SPE2DB20D1100-SPE2DB25FE0WV
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $120,192.80 by the Defense Logistics Agency on September 18, 2025, for the supply of Ocrevus 300 mg/10 ml vials. This firm fixed-price delivery order, which carries an ultimate completion date of October 9, 2025, represents a competitively awarded contract with no set-aside designation. The contract will be fulfilled from the vendor's Conshohocken,...
- The Defense Logistics Agency awarded a $48,077.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on September 19, 2025, with an ultimate completion date of October 10, 2025. This non-competitive delivery order was placed against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $24,038.58 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on August 18, 2025. The contract is firm fixed price with no set-aside designation and is scheduled for completion by September 9, 2025. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Ocrevus 300 mg/10 ml vials. The contract, valued at $120,192.80 with a firm fixed price structure, represents a competitively awarded, non-set-aside delivery order with an ultimate completion date of October 8, 2025. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $48,077.16 firm fixed price delivery order to AmerisourceBergen Drug Corp for 10 milliliter vials of Ocrevus 300 mg on September 10, 2025, with an ultimate completion date of October 1, 2025. This contract was not set-aside and represents a competitive award to the pharmaceutical distributor. Performance will occur at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child delivery order, this award falls under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Ocrevus 300 mg/10 ml vials with a ceiling value of $85,193.27. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is scheduled for completion by August 4, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Ocrevus 300 mg/10 mL vials valued at $48,077.16. This is a firm fixed-price delivery order with an ultimate completion date of October 9, 2025, and represents a non-competitive award under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contract will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency has awarded a delivery order valued at $120,192.80 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 ml vials. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of May 15, 2025. The awardee, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $72,115.74 to AmerisourceBergen Drug Corp for the supply of Ocrevus (300 mg/10 mL vial) pharmaceutical product. This is a firm fixed price, non-set-aside contract with an ultimate completion date of October 2, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran...
- The Defense Logistics Agency awarded a $136,567.97 delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus (ocrelizumab) 300 mg/10 mL vials on April 24, 2025, with completion expected by May 15, 2025. This firm fixed-price contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE0WVDelivery Order
The Defense Logistics Agency awarded a $240,385.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This is a competitive award with no set-aside designation, with a completion date of October 15, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and serves as a major pharmaceutical distributor supporting federal medical procurement needs. This delivery order is a child contract issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of medications, vaccines, and medical supplies to support military and federal healthcare systems worldwide. AmerisourceBergen's extensive portfolio of federal contract awards demonstrates its capability to meet complex medical procurement requirements across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical devices for defense and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $240.4k | 9/23/25 |